- Home
- REGN vs TRP Comparison
REGN vs TRP Comparison
Compare REGN & TRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- TRP
- Stock Information
- Founded
- REGN 1988
- TRP 1951
- Country
- REGN United States
- TRP Canada
- Employees
- REGN N/A
- TRP N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- TRP
- Sector
- REGN Health Care
- TRP
- Exchange
- REGN Nasdaq
- TRP Nasdaq
- Market Cap
- REGN 59.5B
- TRP 54.1B
- IPO Year
- REGN 1991
- TRP N/A
- Fundamental
- Price
- REGN $560.00
- TRP $52.33
- Analyst Decision
- REGN Buy
- TRP Hold
- Analyst Count
- REGN 23
- TRP 3
- Target Price
- REGN $794.83
- TRP $62.00
- AVG Volume (30 Days)
- REGN 972.9K
- TRP 1.7M
- Earning Date
- REGN 10-30-2025
- TRP 11-06-2025
- Dividend Yield
- REGN 0.63%
- TRP 4.78%
- EPS Growth
- REGN 5.03
- TRP 23.31
- EPS
- REGN 39.67
- TRP 2.99
- Revenue
- REGN $14,214,200,000.00
- TRP $10,486,413,556.00
- Revenue This Year
- REGN N/A
- TRP $11.99
- Revenue Next Year
- REGN $4.86
- TRP $5.28
- P/E Ratio
- REGN $14.12
- TRP $17.49
- Revenue Growth
- REGN 5.38
- TRP 15.85
- 52 Week Low
- REGN $476.49
- TRP $40.79
- 52 Week High
- REGN $1,170.58
- TRP $52.49
- Technical
- Relative Strength Index (RSI)
- REGN 46.27
- TRP 64.49
- Support Level
- REGN $552.98
- TRP $51.67
- Resistance Level
- REGN $570.76
- TRP $52.39
- Average True Range (ATR)
- REGN 15.16
- TRP 0.70
- MACD
- REGN -2.91
- TRP -0.04
- Stochastic Oscillator
- REGN 16.26
- TRP 92.92
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About TRP TC Energy Corporation
TC Energy operates natural gas transmission assets across North America. Segments are determined by country of operation, but both Canadian and US operations are interconnected. Mexican operations are disconnected from the US and only have one customer, the state utility CFE. They also operate power generation assets, with the largest being the Bruce Power nuclear plant.